Deletion of the MSI2 RRM1 reduced the oncogenicity of the MSI2-HOXA9 fusion in vitro and in vivo, resulting in a disease similar to BCR-ABL alone as chimerism and survival were similar to the CML model. This evidence concerns the gene HOXA9 and chronic myelogenous leukemia, BCR-ABL1 positive.